Madrigal Reports $431.3 Million Revenue and $55.4 Million Net Income

What happened

Madrigal Pharmaceuticals reported third-quarter revenue of $431.3 million, 50% higher than a year earlier, and net income of $55.4 million. Reports call this its first profitable quarter. They also say Rezdiffra sales topped $1.1 billion year to date.

Global impact / market context

Higher revenue and a reported profit may matter to investors assessing the company’s business progress. But management expects continued investment and near-term changes in earnings, so this quarter alone does not show whether profit will continue.

What to watch

1. Check the next revenue report to see whether revenue continues to grow; the reported increase was 50% from a year earlier.
2. Check the next profit report to see whether the company remains profitable; this was reported as its first profitable quarter.
3. Check updates on F4c trials and planned investment; the reports say the trials support expansion and management expects continued investment and near-term changes in earnings.

Affected assets

• Madrigal Pharmaceuticals

Evidence

• Infoway News — MDGL: Sales surged 50%, first-quarter profitability arrived, and F4c expansion advanced 2026-11-03T16:57:55+00:00
• Infoway News — Madrigal Reports $431.3 Million Revenue and $55.4 Million Net Income 2026-11-03T13:13:10+00:00
• Infoway News — Madrigal Pharmaceuticals 3Q Rev $431.3M >MDGL 2026-11-03T12:09:00+00:00
• Infoway News — MDGL: Rezdiffra sales topped $1.1B YTD as Q3 delivered first-quarter profitability 2026-11-03T12:08:02+00:00
• Incident timeline — MDGL: Sales surged 50%, first-quarter profitability arrived, and F4c expansion advanced
• Incident timeline — Madrigal Reports $431.3 Million Revenue and $55.4 Million Net Income
• Incident timeline — Madrigal Pharmaceuticals 3Q Rev $431.3M >MDGL
• Incident timeline — MDGL: Rezdiffra sales topped $1.1B YTD as Q3 delivered first-quarter profitability